Zacks Investment Research upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a sell rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “Phibro saw improvement across all broader segments in recent times. The company also seems to be upbeat about its strength in the international business within Animal Health. Additionally, Phibro is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties as well as vaccine technologies. The company is also preparing to foray into the companion animal segment. On the flip side, contraction in the company's operating margin in the last reported quarter is disappointing. Persistently weak dairy industry within the Animal Heath arm also disappoints us. Over the past six months, Phibro has been underperforming its industry.”
Several other analysts have also recently weighed in on the company. BidaskClub upgraded Phibro Animal Health from a sell rating to a hold rating in a report on Tuesday, October 16th. ValuEngine cut Phibro Animal Health from a buy rating to a hold rating in a report on Monday, November 12th. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $43.50.
Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Tuesday, November 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.03). Phibro Animal Health had a return on equity of 38.91% and a net margin of 7.89%. The business had revenue of $200.20 million for the quarter, compared to the consensus estimate of $203.99 million. During the same period in the previous year, the company posted $0.38 earnings per share. Phibro Animal Health’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities research analysts expect that Phibro Animal Health will post 1.71 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 19th. Shareholders of record on Wednesday, November 28th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.50%. The ex-dividend date of this dividend was Tuesday, November 27th. This is an increase from Phibro Animal Health’s previous quarterly dividend of $0.10. Phibro Animal Health’s dividend payout ratio is 27.59%.
In other news, insider Dean J. Warras sold 10,000 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $42.84, for a total transaction of $428,400.00. Following the completion of the transaction, the insider now owns 10,000 shares in the company, valued at approximately $428,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dean J. Warras sold 21,560 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $31.81, for a total value of $685,823.60. Following the transaction, the insider now owns 21,560 shares of the company’s stock, valued at approximately $685,823.60. The disclosure for this sale can be found here. Insiders sold a total of 41,560 shares of company stock valued at $1,436,199 in the last 90 days. Corporate insiders own 50.29% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in Phibro Animal Health by 5.2% during the 3rd quarter. BlackRock Inc. now owns 3,475,601 shares of the company’s stock worth $149,103,000 after purchasing an additional 171,160 shares in the last quarter. Vanguard Group Inc lifted its holdings in Phibro Animal Health by 3.3% during the 3rd quarter. Vanguard Group Inc now owns 2,074,840 shares of the company’s stock worth $89,011,000 after purchasing an additional 66,676 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Phibro Animal Health by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,074,840 shares of the company’s stock worth $89,011,000 after purchasing an additional 66,676 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Phibro Animal Health by 26.7% during the 3rd quarter. Renaissance Technologies LLC now owns 803,800 shares of the company’s stock worth $34,483,000 after purchasing an additional 169,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Phibro Animal Health by 1.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 511,279 shares of the company’s stock worth $21,933,000 after purchasing an additional 8,754 shares in the last quarter. Institutional investors own 49.73% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Read More: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.